» Articles » PMID: 15211441

The Effect of N-3 Fatty Acids on Plasma Lipids and Lipoproteins and Blood Pressure in Patients with CRF

Overview
Journal Am J Kidney Dis
Specialty Nephrology
Date 2004 Jun 24
PMID 15211441
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patients with chronic renal failure (CRF) have a high incidence of cardiovascular disease and increased premature mortality. n-3 Polyunsaturated fatty acids (PUFAs) are known to decrease plasma triglyceride levels, reduce blood pressure (BP), and have a cardioprotective effect in subjects with normal renal function. The aim of this study is to examine the effect of n-3 PUFAs on plasma lipid and lipoprotein levels and 24-hour ambulatory BP in patients with CRF.

Methods: Sixty-four patients with CRF, defined as a plasma creatinine level between 1.70 and 4.52 mg/dL (150 and 400 micromol/L), were included and randomly assigned to treatment with 2.4 g of n-3 PUFAs or control treatment (olive oil) for 8 weeks. Patients were evaluated by measurement of fasting plasma lipid and lipoprotein levels and 24-hour ambulatory BP recordings before and after the supplements. n-3 PUFA content was determined in cell membranes of granulocytes and adipose tissue samples to evaluate n-3 PUFA intake.

Results: There was a significant 8% increase in high-density lipoprotein cholesterol levels (P < 0.01) and a significant 21% decrease in serum triglyceride levels (P < 0.02) in the group administered n-3 PUFA supplements. There were no changes in total cholesterol or low-density lipoprotein cholesterol levels in any group, and n-3 PUFAs had no effect on 24-hour ambulatory BP.

Conclusion: Supplementation with n-3 PUFAs had a favorable effect on lipoprotein profile in patients with CRF, whereas no effect on 24-hour ambulatory BP was observed.

Citing Articles

Antioxidants for adults with chronic kidney disease.

Colombijn J, Hooft L, Jun M, Webster A, Bots M, Verhaar M Cochrane Database Syst Rev. 2023; 11:CD008176.

PMID: 37916745 PMC: 10621004. DOI: 10.1002/14651858.CD008176.pub3.


Associations of the Healthy Eating Index-2010 with risk of all-cause and heart disease mortality among adults with hypertension: Results from the National Health and Nutrition Examination Survey 2007-2014.

Zhang Y, Li D, Zhang H Front Nutr. 2023; 10:1077896.

PMID: 36937360 PMC: 10020655. DOI: 10.3389/fnut.2023.1077896.


Effect of Omega-3 Fatty Acids Supplementation on Homocysteine Level in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis.

Gholipur-Shahraki T, Vahdat S, Seirafian S, Pourfarzam M, Badri S J Res Pharm Pract. 2023; 11(2):80-86.

PMID: 36798100 PMC: 9926915. DOI: 10.4103/jrpp.jrpp_67_22.


Recent Progress on Lipid Intake and Chronic Kidney Disease.

Pei K, Gui T, Li C, Zhang Q, Feng H, Li Y Biomed Res Int. 2020; 2020:3680397.

PMID: 32382547 PMC: 7196967. DOI: 10.1155/2020/3680397.


Omega-3 Supplementation in the Prevention of Contrast Induced Nephropathy in Patients Undergoing Elective Percutaneous Coronary Intervention: A Randomized Placebo-Controlled Trial.

Foroughinia F, Mirjalili M, Mirzaei E, Oboodi A Adv Pharm Bull. 2019; 9(2):307-313.

PMID: 31380258 PMC: 6664110. DOI: 10.15171/apb.2019.036.